Cargando…
Repurposing Tranexamic Acid as an Anticancer Agent
Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Previous studies suggested that TA may exhibit anticancer acti...
Autores principales: | Law, Mary E., Davis, Bradley J., Ghilardi, Amanda F., Yaaghubi, Elham, Dulloo, Zaafir M., Wang, Mengxiong, Guryanova, Olga A., Heldermon, Coy D., Jahn, Stephan C., Castellano, Ronald K., Law, Brian K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793890/ https://www.ncbi.nlm.nih.gov/pubmed/35095503 http://dx.doi.org/10.3389/fphar.2021.792600 |
Ejemplares similares
-
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway
por: Wang, Mengxiong, et al.
Publicado: (2019) -
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015) -
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells
por: Ferreira, Renan B., et al.
Publicado: (2017) -
Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
por: Ma, Zhaowu, et al.
Publicado: (2021) -
Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)